Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cance... ( EAST HANOVER N.J. Dec. 9 2010 /- A ne...)

HOME >> MEDICINE >> TECHNOLOGY

Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients

Date:12/9/2010

EAST HANOVER, N.J., Dec. 9, 2010 /PRNewswire/ -- A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas(1).

Findings from a randomized, Phase II study of 111 patients showed the proportion of metastatic breast cancer patients without tumor progression at six months was 61.1% for those taking everolimus plus tamoxifen (95% confidence interval [CI], 46.9 to 74.1) versus 42.1% for patients treated with tamoxifen alone (95% CI, 29.1 to 55.9); p=0.045(1).

Disease progression was delayed by a median of 8.6 months in patients treated with the combination versus 4.5 months in patients treated with tamoxifen alone, with everolimus in combination with tamoxifen providing a statistically significant reduction in the risk of disease progression by 47% (hazard ratio=0.53 [95% CI, 0.35 to 0.81]; log-rank test: p=0.0026, exploratory analysis). Side effects were generally manageable in both study arms. As of October 2010, there were 25 patient deaths in the tamoxifen arm versus nine in the everolimus plus tamoxifen arm (hazard ratio=0.32 [95% CI, 0.15 to 0.68]; log-rank test: p=0.0019)(1).

This Phase II trial is conducted by the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (the French GINECO Group).

Everolimus is an investigational agent for the treatment of patients with breast cancer. Everolimus targets mTOR in cancer cells, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(7,8).

"The almost doubling of time to di
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Post Your Comments:

(Date:6/17/2013)... WASHINGTON , June 17, 2013 ... ) presented additional data today at ENDO 2013, ... demonstrating that tasimelteon can entrain (synchronize) both melatonin ... potential to reset the master body clock and ... Non-24-Hour Disorder (Non-24). The SET (Safety and Efficacy ...

(Date:6/17/2013)... 17, 2013 DNAtrix Inc., experts in oncolytic ... clinical data on the company,s lead product, DNX-2401, at ... Quebec City, Canada on June 18, 2013. ... and a leader in the field of oncolytic virus ... A PHASE I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS ...

(Date:6/17/2013)... BioMed Realty Trust, Inc. (NYSE: BMR ... a second quarter 2013 dividend of $0.235 per share of ... of $0.94 per common share. The common ... of record at the close of business on June 28, ... BioMed Realty delivers optimal real estate solutions for biotechnology and ...

Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2 Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3 Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4 DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2 BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2 BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3

[0] Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder [0] DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus [0] BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend

... market research report is available in its catalogue: , , , ... , , ... Reports details , , , ... high, growing demand worldwide? , , , ...

... Cochlear, the global leader in implantable hearing ... Clark Cochlear Scholarship. Presented by Cochlear Americas, the Graeme ... seniors who,ve demonstrated exceptional achievements both in the classroom ... implant and will receive financial assistance toward their chosen ...

Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 Cochlear Americas Honors Achievements of Cochlear Implant Recipients during May's Better Hearing & Speech Month

(Date:6/18/2013)... The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... President’s Emergency Plan for AIDS Relief (PEPFAR) to mark ... in the global effort to eliminate pediatric HIV/AIDs. ... of June 2013, one million babies globally have been ... inception in 2003, EGPAF has been a key implementer ...

(Date:6/18/2013)... Park City, UT (PRWEB) June 18, 2013 ... employees on Health Reimbursement Accounts . Zane Benefits, ... sponsored health benefits, is the leader in defined ... , According to Zane Benefits’ website, employees of a ... Account (HRA) may have questions about how Health Reimbursement ...

(Date:6/18/2013)... York, N.Y., June 18, 2013 -- Lauren Sciences, ... novel V-Smart nanovesicle platform technology, announced today that ... in Drug Delivery with its V-Smart Platform, and ... report by MCD Group. , The ... of Start-ups and Emerging Companies ," features companies ...

(Date:6/18/2013)... Brandeis research scientist Daniel Perlman has discovered a way ... and foods that are consumed by humans, potentially opening ... , A U.S. patent (#8,460,738) on the new process ... , Phytosterols in plants and cholesterol molecules in animals ... they are attracted to one another. When they mix ...

(Date:6/18/2013)... Coral Springs, FL (PRWEB) June 18, 2013 ... offer the best education for students around the country. ... where student life is enriched by the areas or ... segment about the benefits of attending one of these ... The enlightening show informs viewers of the educational facilities ...

Breaking Medicine News(10 mins):Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2 Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3 Health News:Zane Benefits Publishes New Information on Health Reimbursement Accounts 2 Health News:Brandeis scientist invents anti-cholesterol process 2 Health News:Editions TV Presents a Segment on the Higher Education Hidden Gems 2

[0] One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS [0] Zane Benefits Publishes New Information on Health Reimbursement Accounts [0] Lauren Sciences independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in new report by MCD Group [0] Brandeis scientist invents anti-cholesterol process [0] Editions TV Presents a Segment on the Higher Education Hidden Gems

... Public,Dollars, WASHINGTON, Dec. 14 HHS Secretary ... waiver that will allow,the state of Indiana to ... low-income, uninsured residents access to critical,health care services. ... to begin,accepting applications for the new health care ...

... history of abuse by intimate partners have higher health care ... according to a study conducted at Group Health, a Seattle-based ... the cost of providing care and use of health serviceswere ... born, the research team found. Scientists from Group Health ...

... Program Bolstered by Celebrity Support, WASHINGTON, Dec. ... for supportive cards, especially during,the holiday season. Thousands ... the,American Red Cross for delivery to hospitalized service ... his wife, Elizabeth, heard,about the program and decided ...

... KENILWORTH, N.J., Dec. 14 The Board of,Directors of ... dividend of 6.5 cents per common share. Payment will ... at the close of business on Feb.,1, 2008. As ... The Board of Directors today also declared a ...

... Mike Sacco and Lejon,Boudreaux are running a minimum of ... reckless drivers and tons of highway,debris to get a ... Release, go to:, http://www.prnewswire.com/mnr/blackaidsinstitute/31094/ , "We want 1 ... 2009,which is National HIV Testing Day," says Sacco, 26, ...

... nothing to clear the nose, studies suggest , , FRIDAY, ... of U.S. Food and Drug Administration (FDA) experts is ... cold medicines do nothing to clear nasal congestion. , ... 10 milligrams per dose of phenylephrine. Studies have ...

Cached Medicine News:Health News:HHS Approves Medicaid Waiver to Create New Indiana Health Plan for Uninsured Hoosiers 2 Health News:Health needs higher for kids of abused moms 2 Health News:Health needs higher for kids of abused moms 3 Health News:Randy Travis Participates in American Red Cross Holiday Card Program to Wounded Service Members 2 Health News:Randy Travis Participates in American Red Cross Holiday Card Program to Wounded Service Members 3 Health News:Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles 2 Health News:Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles 3 Health News:FDA Mulls Effectiveness of OTC Cold Remedies 2 Health News:FDA Mulls Effectiveness of OTC Cold Remedies 3 Health News:FDA Mulls Effectiveness of OTC Cold Remedies 4

HHS Approves Medicaid Waiver to Create New Indiana Health Plan for Uninsured Hoosiers Health needs higher for kids of abused moms Randy Travis Participates in American Red Cross Holiday Card Program to Wounded Service Members Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles FDA Mulls Effectiveness of OTC Cold Remedies

Cannulated Interference Screws...

... excellent protection and ease of use. It ... to an adhesive in molecular weight than ... maintain viscosity at high shear rates, giving ... superb performance during capsulorhexis, phaco, IOL insertion, ...

Finally, a camera that sees the way you do!,Combined with the MicroLux DVR (Digital Video Recorder), the MicroLux Headlight Camera System gives you an entirely new way to visualize, edit, share and...

... Optional supine measurement position is achieved ... gantry and a non-magnetic, mobile patient bed. ... outside the shielded room. In case of ... rapidly outside the shielded room for e.g. ...

Medicine Products:

PHANTOM Absorbable Cannulated Interference Screws CoEase (1.2% sodium hyaluronate) viscoelastic solution The MicroLux Headlight Camera System Neuromag-122